Agilent Technologies has expanded SureSelect target-enrichment product family by launching the SureSelect Human All Exon V6, V6+UTR and V6+COSMIC.
The new products will address the current limitations of exome sequencing and gives better coverage of hard-to-capture regions to researchers and provide deep coverage of relevant regions with minimal sequencing.
The company said the new products will enable researchers to delve deeper into both constitutional diseases and cancers by providing up-to-date exome design.
Additionally, the newly launched products cover more regions, increase the sensitivity of variant calling and minimize false negative calls.
SureSelect Human All Exon V6+UTR adds untranslated regions of the exome for translational research, while V6+COSMIC adds data from the cancer research database known as the Catalogue Of Somatic Mutations In Cancer.
Agilent has announced OneSeq, all-in-one target enrichment product for identifying genome-wide copy number variations and mutations this year.
This apart, Agilent has also offered the SureSelect clinical research exome, SureSelect focused exome and ClearSeq inherited disease research panel.
The new products are compatible with the custom design capabilities of SureDesign.
“The Human All Exon V6 is an important addition to our strong NGS portfolio for constitutional disease research. It targets hard-to-capture and multi-mapping regions that had proven challenging for current exome products on the market,” said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group.
Last month Agilent acquired Cartagenia, a provider of software and services for clinical genetics and molecular pathology labs.